Your browser doesn't support javascript.
loading
Fulminant Anti-GAD antibody encephalitis presenting with status epilepticus requiring aggressive immunosuppression.
Triplett, J; Vijayan, S; MacDonald, A; Lawn, N; McLean-Tooke, A; Bynevelt, M; Phatouros, C; Chemmanam, T.
Afiliação
  • Triplett J; Department of Neurology, Sir Charles Gairdner Hospital, Nedlands, Australia.
  • Vijayan S; Department of Neurology, Sir Charles Gairdner Hospital, Nedlands, Australia.
  • MacDonald A; Department of Neurology, Sir Charles Gairdner Hospital, Nedlands, Australia.
  • Lawn N; Department of Neurology, Sir Charles Gairdner Hospital, Nedlands, Australia.
  • McLean-Tooke A; Department of Immunology, Sir Charles Gairdner Hospital, Nedlands, Australia.
  • Bynevelt M; Neurological Intervention and Imaging Service of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia.
  • Phatouros C; Neurological Intervention and Imaging Service of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia.
  • Chemmanam T; Department of Neurology, Sir Charles Gairdner Hospital, Nedlands, Australia. Electronic address: thomas.chemmanam@health.wa.gov.au.
J Neuroimmunol ; 323: 119-124, 2018 10 15.
Article em En | MEDLINE | ID: mdl-30196824
ABSTRACT
Antibodies against glutamic acid decarboxylase (GAD) are reported in association with numerous neurological conditions including temporal lobe epilepsy and limbic encephalitis. We report a case of Anti-GAD-Antibody associated encephalitis presenting with epilepsia partialis continua (EPC) progressing to a fulminant encephalopathy preferentially affecting the frontal lobes associated with coma and refractory status epilepticus. The abnormalities identified on MRI included marked bilateral frontal lobe involvement which has not been reported in other auto-immune encephalitides and may be specific for Anti-GAD-Antibody associated encephalitis. Similar to the majority of cases of Anti-GAD associated neurological disturbance no underlying malignancy was identified. Treatment with high dose corticosteriods, IVIG and plasmapheresis had minimal response, but escalation of treatment with rituximab and cyclophosphamide was associated with clinical improvement, reducing antibody titers and resolution of MRI changes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Autoanticorpos / Estado Epiléptico / Terapia de Imunossupressão / Encefalite / Glutamato Descarboxilase / Imunossupressores Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Female / Humans Idioma: En Revista: J Neuroimmunol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Autoanticorpos / Estado Epiléptico / Terapia de Imunossupressão / Encefalite / Glutamato Descarboxilase / Imunossupressores Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Female / Humans Idioma: En Revista: J Neuroimmunol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Austrália